ImmunoGen touts new drug-delivering antibodies

Tuesday, March 8, 2011 10:33 AM

After forming partnerships with several major pharmaceutical companies, Waltham, Mass.-based biotech ImmunoGen wants to boost its pipeline of antibody-drug conjugates.

ImmunoGen is known for providing the technology for Roche/Genentech's experimental T-DM1, enabling a cancer-killing toxin to be linked to the approved antibody drug Herceptin to treat certain patients with breast cancer. While that is the latest-stage candidate to use ImmunoGen's technology, the firm has its own compounds that could bolster its future prospects.

One of the compounds in an early-stage clinical trial, called IMGN529, is an antibody that targets non-Hodgkin's lymphomas and that includes a special toxin. The toxin is supposed to remain linked to the antibody in a patient's bloodstream, until the compound reaches the targeted cancer site. This approach targets specific tumors with the antibody while delivering a potent toxin against the cancer. ImmunoGen aims to file with the FDA by mid-2011 for approval to begin early human trials with the new compound.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private á¼€nancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs